Comparative Pharmacology
Head-to-head clinical analysis: FLUNISOLIDE versus KENALOG.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUNISOLIDE versus KENALOG.
FLUNISOLIDE vs KENALOG
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory action; inhibits release of inflammatory mediators (e.g., histamine, leukotrienes), reduces eosinophil migration, and stabilizes mast cells. Suppresses cytokine production and adhesion molecule expression.
Triamcinolone acetonide is a synthetic corticosteroid with potent glucocorticoid and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of phospholipase A2, decreased release of arachidonic acid, and reduced synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production and immune cell migration.
50 mcg per nostril twice daily (total daily dose 200 mcg), via nasal spray.
Kenalog (triamcinolone acetonide) 40-80 mg intramuscularly (deep gluteal) every 4 weeks; or 0.5-1 mg/kg intravenously every 24 hours (for acute conditions).
None Documented
None Documented
Clinical Note
moderateFlunisolide + Gatifloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Gatifloxacin."
Clinical Note
moderateFlunisolide + Rosoxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Rosoxacin."
Clinical Note
moderateFlunisolide + Levofloxacin
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Levofloxacin."
Clinical Note
moderateFlunisolide + Trovafloxacin
Terminal elimination half-life is 1.8 hours (range 1.3–2.5 h) after intravenous administration; clinically, endogenous suppression persists up to 24 h post-inhalation.
Terminal half-life ~2-5 hours (triamcinolone acetonide); clinical duration prolonged due to crystalline depot formulation
Renal (50%) as metabolites, fecal (40%) as metabolites via bile, <5% unchanged in urine.
Renal (primarily as metabolites), ~30% unchanged; biliary/fecal minor (≤10%)
Category C
Category C
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Flunisolide is combined with Trovafloxacin."